Breaking News
Get 55% Off 0
NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stock
Read More
Close

Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct Growth (0P0001DJWZ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
40.390 +0.300    +0.75%
22/11 - Closed. Currency in INR
Type:  Fund
Market:  India
ISIN:  INF109KC1GH2 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 50.24B
ICICI Prudential Pharma Healthcare and Diagnostics 40.390 +0.300 +0.75%

0P0001DJWZ Holdings

 
Comprehensive information about top holdings and Key Holding Information for the ICICI Prudential Pharma Healthcare and Diagnostics (0P0001DJWZ) fund. Our ICICI Prudential Pharma Healthcare and Diagnostics portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 2.130 3.310 1.180
Shares 97.870 97.870 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 31.720 37.516
Price to Book 3.965 5.365
Price to Sales 4.253 5.581
Price to Cash Flow 21.381 27.701
Dividend Yield 0.584 0.595
5 Years Earnings Growth 21.429 19.762

Sector Allocation

Name  Net % Category Average
Healthcare 97.740 96.130
Basic Materials 1.350 4.357
Financial Services 0.910 1.163

Region Allocation

  • Asia
  • Africa & Middle East
  • Emerging Markets
  • Developed Markets

Top Holdings

Number of long holdings: 45

Number of short holdings: 1

Name ISIN Weight % Last Change %
  Sun Pharma INE044A01036 14.35 1,795.30 +0.86%
  Dr Reddy’s Laboratories INE089A01031 9.03 1,214.45 +1.60%
  Cipla INE059A01026 8.07 1,486.50 +1.43%
  Lupin INE326A01037 4.59 2,071.35 +1.39%
  Aurobindo Pharma INE406A01037 4.57 1,223.70 +0.30%
  Gland INE068V01023 4.22 1,755.05 -1.79%
  Apollo Hospitals INE437A01024 3.80 6,935.10 +2.86%
  Zydus Lifesciences INE010B01027 2.93 949.05 +0.53%
  Divi's Labs INE361B01024 2.69 5,998.35 +0.36%
  Biocon INE376G01013 2.39 331.50 +2.60%

Top Equity Funds by ICICI Prudential Asset Management Company Limited

  Name Rating Total Assets YTD% 3Y% 10Y%
  ICICI Focused Bluechip Equity RetGr 636.7B 19.57 17.19 14.12
  ICICI Focused Bluechip Eq RetailDiv 636.7B 18.88 16.39 13.30
  ICICI Prud Focused Bluechip Div 636.7B 19.95 17.65 14.65
  ICICI Prud Focused Bluechip Gr 636.7B 20.15 17.90 14.99
  ICICI Balanced Adv Dir Div 605.45B 13.16 12.53 11.67
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0001DJWZ Comments

Write your thoughts about Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct Growth
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email